Language and Dialects

Lumakras®. (LOO-muh-kras). Additional resources. Product Web Site · Prescribing Information · Product Resources. Sotorasib (Lumakras®) is used to treat patients ... Cells readily form othrotopic lung tumors in C57BL/6 mice. This cell line is a suitable model for research regarding therapurtics involving KRASG12C inhibitors. We're here to help KICK CANCER'S KRAS! Knowledge + Research + Advocacy = Survivorship. Educate - Empower - Engage. Sep 10, 2023 ... The findings suggest durable clinical activity of adagrasib for KRAS G12C-mutated NSCLC. “The study data demonstrates compelling results, ... Dec 5, 2023 ... Subsequently additional oncogenic driver alterations in BRAF, RET, KRAS G12C, HER2, MET, NTRK, and ROS1 were identified along with corresponding ... CPT Code(s)*. 81275, 81276. *The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct ... Dec 17, 2024 ... Despite decades of research, effective targeting of KRAS has proven elusive. While small-molecule KRAS inhibitors like Amgen's Lumakras and ... 5 days ago ... Breaking Down the Data: Efficacy That Stands Out. The study enrolled patients with KRAS G12D-mutant NSCLC, a subset of lung cancer that ... LUNGMAP S1900E: KRAS Targeted Therapy Sub-Study. S1900F. A Randomized Phase II ... Lung-MAP Informational Webinar for Advocacy Organizations Aug 2023. LUMAKRAS® is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as ...